Corporate News - Investors | BB Biotech AG

Your browser is out-of-date!

Update your browser to view this website correctly.

BB Biotech AG

Contact
Investment Professionals
de
en
Menu

Results

Your last 6 search terms

Keine Suchergebnisse gefunden.

Bitte versuchen Sie es mit anderen Suchbegriffen oder lassen Sie sich inspirieren.

Insights / News
Investment Solutions
Investor Relations

About BB Biotech
Portfolio & Strategy
ESG
- Sustainability
- Policies
Insights
- Show all Insights
  - 12.11.2025
    BB Biotech Update October 2025
  - 07.11.2025
    Turning milestones into momentum
  - 28.10.2025
    Fourth M&A transaction highlights portfolio strength
  - 15.10.2025
    What Pfizer’s deal with Donald Trump means for global drug pricing
Investors

About BB Biotech
Portfolio & Strategy
ESG
- Sustainability
- Policies
Insights
- Show all Insights
  - 12.11.2025
    - BB Biotech Update October 2025
  - 07.11.2025
    - Turning milestones into momentum
  - 28.10.2025
    - Fourth M&A transaction highlights portfolio strength
  - 15.10.2025
    - What Pfizer’s deal with Donald Trump means for global drug pricing
Investors

Investment Professionals

de
en

Contact

1Cookies

2Disclaimer

This website uses cookies, which are necessary for the technical operation of the website and which are always set. Other cookies to personalize content and analyze access to our website are only set with your consent. We also share information about your use of our website with our social media, advertising and analytics partners.

necessary

statistics

marketing

Disclaimer

To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Individual Investors

Investment Professionals

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Save data on this computer

Important

Principles

By using the website www.bbbiotech.ch, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

All
Media Releases
ad hoc Releases

24.10.2025
BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery
24.10.2025
BB Biotech AG publishes its interim report
22.09.2025
BB Biotech to be included in the SPI ESG Index
25.07.2025
BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
25.07.2025
BB Biotech AG publishes its interim report
25.04.2025
BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility
25.04.2025
BB Biotech AG publishes its interim report
19.03.2025
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
21.02.2025
Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics
21.02.2025
BB Biotech AG publishes its 2024 annual report
24.01.2025
BB Biotech: Preliminary full-year 2024 results and dividend proposal
24.01.2025
BB Biotech AG closes the 2024 fiscal year with a profit
25.10.2024
Strategic reallocation of portfolio assets progressing
25.10.2024
BB Biotech AG publishes its interim report
26.07.2024
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
26.07.2024
BB Biotech AG publishes its interim report and announces a new head of its investment management team
26.04.2024
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
26.04.2024
BB Biotech AG publishes its interim report
21.03.2024
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
16.02.2024
BB Biotech AG publishes its 2023 annual report
19.01.2024
End of year biotech equity market rally – M&A and end of rate hike cycle
19.01.2024
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
20.10.2023
Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
20.10.2023
BB Biotech AG publishes its interim report
21.08.2023
Delisting from Borsa Italiana
21.07.2023
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
21.07.2023
BB Biotech AG publishes its interim report
21.04.2023
Lackluster first quarter for biotech stocks
21.04.2023
BB Biotech AG publishes its interim report
23.03.2023
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
17.02.2023
BB Biotech AG publishes its 2022 annual report
20.01.2023
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
20.01.2023
BB Biotech AG closes the 2022 fiscal year with a loss
21.10.2022
US drug pricing legislation drives biotech business to adapt for further innovation
21.10.2022
BB Biotech AG publishes its interim report
22.09.2022
22.09.2022 Rivus Pharmaceuticals Closes $132 Million Series B with participation of BB Biotech
22.07.2022
First signs of increased M&A activity due to attractive valuations
22.07.2022
BB Biotech AG publishes its interim report
22.04.2022
Increased investment level balanced by established core holdings
22.04.2022
BB Biotech AG publishes its interim report
12.04.2022
BB Biotech AG concludes its share buyback program and launches a new buyback program
17.03.2022
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
18.02.2022
BB Biotech AG publishes its 2021 annual report
21.01.2022
2021 was a difficult year for biotech equity markets – increased dividend of CHF 3.85 proposed
21.01.2022
BB Biotech AG closes the 2021 fiscal year with a loss
22.10.2021
BB Biotech increases positions in oncology and CNS
22.10.2021
BB Biotech AG publishes interim report
23.07.2021
Solid second quarter for the biotech industry
23.07.2021
BB Biotech AG publishes interim report
23.04.2021
Sector re-valuation used for portfolio investments
23.04.2021
BB Biotech AG publishes interim report
18.03.2021
Shareholders at BB Biotech AG’s AGM approve all proposals
19.02.2021
BB Biotech AG publishes its 2020 annual report
22.01.2021
Vaccines leading the way out of the pandemic
22.01.2021
BB Biotech AG closes the 2020 fiscal year with a profit
23.10.2020
BB Biotech AG publishes interim report
23.10.2020
Biotech M&A picks up
24.07.2020
BB Biotech AG publishes its interim report
24.07.2020
Innovative biotech companies lead efforts
24.04.2020
Resilient biotech sector despite widespread market turmoil
24.04.2020
BB Biotech AG publishes its interim report
02.04.2020
«Coronavirus ist primär kein Investment Case» (in German)
19.03.2020
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals
21.02.2020
BB Biotech AG publishes its 2019 annual report
17.01.2020
BB Biotech benefits from M&A transactions
17.01.2020
BB Biotech AG closes the 2019 fiscal year with a profit
20.11.2019
Expansion of the Board of Directors
18.10.2019
Political factors weigh on biotech equity markets
18.10.2019
BB Biotech AG publishes its interim report
19.07.2019
Consolidation leaves a mark on results
19.07.2019
BB Biotech AG publishes its interim report
26.04.2019
Strong 1st quarter for BB Biotech
26.04.2019
BB Biotech AG reports results
11.04.2019
Completion of the current share buyback program
21.03.2019
Results Annual General Meeting
15.02.2019
BB Biotech AG publishes its 2018 annual report
23.01.2019
Starker Jahresauftakt für die Biotechbranche (in German)
18.01.2019
BB Biotech invests gains of M&A transactions in new technologies
18.01.2019
BB Biotech AG closes the 2018 fiscal year with a loss

contact

BB Biotech AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland

+41 52 624 08 45 info@bbbiotech.ch

Quick Links

BB Biotech AG
Investment Strategy
Insights
Investment Manager
Share Price
Financial Reporting

Subscribe Newsletter

LinkedIn Twitter

Disclaimer
Data Protection
Conditions of use